Development of Molecules Antagonizing Heparan Sulfate Proteoglycans.


Journal

Seminars in thrombosis and hemostasis
ISSN: 1098-9064
Titre abrégé: Semin Thromb Hemost
Pays: United States
ID NLM: 0431155

Informations de publication

Date de publication:
Apr 2021
Historique:
entrez: 1 4 2021
pubmed: 2 4 2021
medline: 29 10 2021
Statut: ppublish

Résumé

Heparan sulfate proteoglycans (HSPGs) occur in almost every tissue of the human body and consist of a protein core, with covalently attached glycosaminoglycan polysaccharide chains. These glycosaminoglycans are characterized by their polyanionic nature, due to sulfate and carboxyl groups, which are distributed along the chain. These chains can be modified by different enzymes at varying positions, which leads to huge diversity of possible structures with the complexity further increased by varying chain lengths. According to their location, HSPGs are divided into different families, the membrane bound, the secreted extracellular matrix, and the secretory vesicle family. As members of the extracellular matrix, they take part in cell-cell communication processes on many levels and with different degrees of involvement. Of particular therapeutic interest is their role in cancer and inflammation as well as in infectious diseases. In this review, we give an overview of the current status of medical approaches to antagonize HSPG function in pathology.

Identifiants

pubmed: 33794555
doi: 10.1055/s-0041-1725067
doi:

Substances chimiques

Heparan Sulfate Proteoglycans 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

316-332

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Tanja Gerlza (T)

Karl-Franzens University Graz, Institute of Pharmaceutical Sciences, Graz, Austria.

Christina Trojacher (C)

Karl-Franzens University Graz, Institute of Pharmaceutical Sciences, Graz, Austria.

Nikola Kitic (N)

Karl-Franzens University Graz, Institute of Pharmaceutical Sciences, Graz, Austria.

Tiziana Adage (T)

Antagonis Biotherapeutics GmbH, Graz, Austria.

Andreas J Kungl (AJ)

Karl-Franzens University Graz, Institute of Pharmaceutical Sciences, Graz, Austria.
Antagonis Biotherapeutics GmbH, Graz, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH